Fortress Biotech, Inc.

NasdaqCM:FBIO Stock Report

Market Cap: US$34.6m

Fortress Biotech Valuation

Is FBIO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of FBIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate FBIO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate FBIO's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for FBIO?

Other financial metrics that can be useful for relative valuation.

FBIO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.3x
Enterprise Value/EBITDA-0.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does FBIO's PS Ratio compare to its peers?

The above table shows the PS ratio for FBIO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average18.1x
CYTH Cyclo Therapeutics
33.6x62.9%US$36.2m
APM Aptorum Group
35.5xn/aUS$42.5m
ICCC ImmuCell
2.2xn/aUS$38.9m
CASI CASI Pharmaceuticals
1x27.1%US$33.8m
FBIO Fortress Biotech
0.4x14.1%US$34.6m

Price-To-Sales vs Peers: FBIO is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (18.1x).


Price to Earnings Ratio vs Industry

How does FBIO's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.8%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.8%
n/an/an/a
No more companies

Price-To-Sales vs Industry: FBIO is good value based on its Price-To-Sales Ratio (0.4x) compared to the US Biotechs industry average (13.2x).


Price to Sales Ratio vs Fair Ratio

What is FBIO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

FBIO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.4x
Fair PS Ratio0.9x

Price-To-Sales vs Fair Ratio: FBIO is good value based on its Price-To-Sales Ratio (0.4x) compared to the estimated Fair Price-To-Sales Ratio (0.9x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst FBIO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.80
US$10.75
+497.2%
74.2%US$24.00US$4.00n/a4
Apr ’25US$1.99
US$6.33
+218.3%
41.4%US$10.00US$4.00n/a3
Feb ’25US$1.97
US$39.50
+1,905.1%
89.9%US$75.00US$4.00n/a2
Jan ’25US$3.01
US$39.50
+1,212.3%
89.9%US$75.00US$4.00n/a2
Dec ’24US$2.17
US$31.33
+1,343.9%
99.6%US$75.00US$4.00n/a3
Nov ’24US$1.68
US$53.25
+3,069.6%
31.0%US$75.00US$30.00n/a4
Oct ’24US$4.35
US$53.25
+1,122.9%
31.0%US$75.00US$30.00n/a4
Sep ’24US$5.98
US$57.60
+863.1%
29.7%US$75.00US$30.00n/a5
Aug ’24US$8.49
US$57.94
+582.1%
30.7%US$75.00US$33.75n/a4
Jul ’24US$8.25
US$57.94
+602.3%
30.7%US$75.00US$33.75n/a4
Jun ’24US$8.17
US$64.35
+687.2%
31.8%US$90.00US$33.75n/a5
May ’24US$11.74
US$74.70
+536.1%
26.0%US$90.00US$37.50n/a5
Apr ’24US$12.30
US$76.50
+522.0%
26.6%US$90.00US$37.50US$1.995
Mar ’24US$11.25
US$76.50
+580.1%
26.6%US$90.00US$37.50US$2.435
Feb ’24US$13.52
US$88.75
+556.3%
37.3%US$150.00US$37.50US$1.976
Jan ’24US$9.82
US$88.75
+803.3%
37.3%US$150.00US$37.50US$3.016
Dec ’23US$9.92
US$91.25
+819.9%
32.3%US$150.00US$52.50US$2.176
Nov ’23US$13.24
US$91.25
+588.9%
32.3%US$150.00US$52.50US$1.686
Oct ’23US$12.90
US$91.25
+607.4%
32.3%US$150.00US$52.50US$4.356
Sep ’23US$15.60
US$91.25
+484.9%
32.3%US$150.00US$52.50US$5.986
Aug ’23US$12.96
US$91.50
+606.0%
35.3%US$150.00US$52.50US$8.495
Jul ’23US$12.00
US$97.50
+712.5%
35.1%US$150.00US$52.50US$8.255
Jun ’23US$11.97
US$97.50
+714.3%
35.1%US$150.00US$52.50US$8.175
May ’23US$16.50
US$99.00
+500.0%
32.6%US$150.00US$60.00US$11.745
Apr ’23US$21.00
US$99.00
+371.4%
32.6%US$150.00US$60.00US$12.305

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.